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This study aims at establishing relationships between genetic and non-genetic factors of variation of the pharmacokinetics of
irinotecan and its metabolites; and also at establishing relationships between the pharmacokinetic or metabolic parameters and the
efficacy and toxicity of irinotecan. We included 49 patients treated for metastatic colorectal cancer with a combination of
5-fluorouracil and irinotecan; a polymorphism in the UGT1A1 gene (TA repeat in the TATA box) and one in the CES2 gene
promoter (830C4G) were studied as potential markers for SN-38 glucuronidation and irinotecan activation, respectively; and the
potential activity of CYP3A4 was estimated from cortisol biotransformation into 6b-hydroxycortisol. No pharmacokinetic parameter
was directly predictive of clinical outcome or toxicity. The AUCs of three important metabolites of irinotecan, SN-38, SN-38
glucuronide and APC, were tentatively correlated with patients’ pretreatment biological parameters related to drug metabolism
(plasma creatinine, bilirubin and liver enzymes, and blood leukocytes). SN-38 AUC was significantly correlated with blood leukocytes
number and SN-38G AUC was significantly correlated with plasma creatinine, whereas APC AUC was significantly correlated with
plasma liver enzymes. The relative extent of irinotecan activation was inversely correlated with SN-38 glucuronidation. The TATA
box polymorphism of UGT1A1 was significantly associated with plasma bilirubin levels and behaved as a significant predictor for
neutropoenia. The level of cortisol 6b-hydroxylation predicted for the occurrence of diarrhoea. All these observations may improve
the routine use of irinotecan in colorectal cancer patients. UGT1A1 genotyping plus cortisol 6b-hydroxylation determination could
help to determine the optimal dose of irinotecan.
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Colorectal adenocarcinoma is a leading cause of cancer in
developed countries and is responsible for 16000 deaths every
year in France (Hill and Doyon, 2005) and 200000 in Europe
(Boyle and Ferlay, 2005). This is a curable disease as long as
metastatic dissemination has not occurred, and even in that case,
the combination of chemotherapy and surgical removing of
hepatic metastases is sometimes able to cure the patient (Bentrem
et al, 2005). Colorectal cancer was considered 20 years ago as a
globally chemoresistant disease and the only available drug was
5-fluorouracil (5-FU), which, however, provided low response
rates and limited survival enhancement. Progress came first from
a better understanding of 5-FU pharmacology: the combination
with folinic acid and the prolongation of drug infusion have
considerably improved the efficiency of single-drug 5-FU therapy
(Labianca et al, 1997). In addition, the discovery of several major
active drugs, namely irinotecan and oxaliplatin, has completely
modified our perception of chemosensitivity of colorectal cancer
(Douillard et al, 2000; de Gramont et al, 2000). Palliative treatment
of metastatic colorectal cancer is now based on the combination
of folinic acid-modulated 5-FU (or another thymidylate synthase
inhibitor) with either irinotecan or oxaliplatin, and allows to
obtain response rates in the range of 40–60% with an overall
survival benefit of more than 24 months (Taieb et al, 2005). This
success has encouraged the use of such combinations in the
adjuvant setting. Finally, the introduction of therapeutic antibodies
directed against the EGF receptor or VEGF has further refined the
treatment protocols (Cunningham et al, 2004; Moses et al, 2004).
The choice of the chemotherapy regimen appears critical: in view
of the impressive survival advantage that can be expected in the
palliative setting, and in view of the possible curability, it is crucial
to offer to every patient the maximum likelihood of drug efficacy.
We have currently no rational way to choose one combination over
the other(s), in particular no predictive test allowing to select
irinotecan or oxaliplatin to be combined with 5-FU. If there is some
drug selectivity, it would be of utmost interest to identify the
parameters that determine this selectivity to prescribe the drug or
drug combination the most likely to provide a response and a
survival advantage to a given patient. In addition, it would be also
important to predict for drug-associated toxicity to avoid the
prescription of a drug with a high risk of neutropoenia, diarrhoea
or mucosal damage. Furthermore, we need to identify individual
parameters that are predictive of drug-induced toxicity.
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(Rivory and Robert, 1995) for several reasons: (i) it is a prodrug
that needs activation to a metabolite, SN-38, to interact with its
target, DNA-topoisomerase I (Top1); this activation, which is
catalysed by carboxylesterase 2 (CES2), is believed to mainly occur
in the liver, but in situ activation in the tumour cell cannot be
ruled out; (ii) irinotecan and SN-38 are subject to metabolism to
inactive species: irinotecan is detoxified by cytochrome P450
CYP3A4 to APC and NPC, whereas SN-38 is conjugated to
glucuronic acid by UDP-glucuronosyl transferase UGT1A1 and
possibly other isoforms; (iii) all camptothecins derivatives and
metabolites are subject to spontaneous interconversion between a
lactone (active) form and a carboxylate (inactive) form, depending
on the pH of the fluid. Several enzymes involved in irinotecan
metabolism present individual variations that may be of
genetic origin: it is well known that the CYP3A4 liver concentra-
tions may vary in a 1:20 ratio, which has been shown to depend
on environmental factors rather than on gene polymorphisms
(Lamba et al, 2002); furthermore, UGT1A1 promoter is subject to a
frequent polymorphism, leading to decreased activity, low SN-38
detoxification and increased risk for irinotecan toxicity (Iyer et al,
2002); finally, little is known about the polymorphisms of CES2 but a
polymorphism occurring in the promoter might well be responsible
for decreased enzyme expression (Charasson et al, 2004).
We wanted in this study to establish the relationships that may
exist between the genetic (gene polymorphisms) and non-genetic
(CYP3A4 status) factors of variation of the metabolic transforma-
tions of irinotecan and the pharmacokinetics of the drug and its
metabolites; and, further, to establish relationships between the
pharmacokinetic or metabolic parameters and the efficacy and
toxicity of irinotecan. A number of biological parameters
potentially indicative of the drug elimination ability of the patients
(plasma creatinine, bilirubin and liver enzymes) were studied at
the onset of the treatment for studying their association with the
pharmacokinetic parameters. This was achieved in a group of 49
patients treated for metastatic colorectal cancer with a combina-
tion of 5-FU and irinotecan; the pharmacokinetics of irinotecan
and its metabolites were studied in all patients; the polymorphisms
of UGT1A1 and CES2 were studied as potential markers for SN-38
glucuronidation and irinotecan activation, respectively; and the
potential activity of CYP3A4 was estimated from cortisol
biotransformation into 6b-hydroxycortisol (Yamamoto et al,
2000).
PATIENTS AND METHODS
Patients
The patients included in this study suffered from advanced or
metastatic colorectal cancer, which had been histologically proven,
and had never been treated with irinotecan. They could have
received folinic acid-modulated 5-FU treatment as adjuvant or
palliative therapy. Patients had to be between 18 and 85 years, with
normal biochemical and haematological tests and a performance
status p2, evaluated as defined by the World Health Organization
(WHO). They were followed regularly all along the evolution of the
disease, and computed tomography scans were performed every 2
months for the evaluation of drug response and event-free survival.
They were treated with the FOLFIRI regimen (Andre ´ et al, 1999),
and their treatment included folinic acid 400mgm
 2 as a 2-h i.v.
infusion; 5-FU 400mgm
 2 i.v. bolus at J1, then 2400mgm
 2 as i.v.
infusion over 46h; and irinotecan 180mgm
 2 as a 1.5-h infusion.
Courses were repeated every 2 weeks. Tumour response was
assessed according to Response Evaluation Criteria in Solid Tumors
(RECIST) criteria and in reviewing computed tomography scans.
All adverse events, especially gastrointestinal events and leuko-
poenia were recorded and graded for severity according to WHO
scales. All the patients enrolled had given informed consent to the
study, which had been approved by the Comite ´ de protection des
personnes dans la recherche biome ´dicale of Bordeaux.
Pharmacokinetic studies
For pharmacokinetic studies, blood samples were obtained from
the first 28 patients, at the first course of treatment, at 1 and 1.5h
after the beginning of irinotecan infusion and then at 10, 30,
45min, 1, 2, 4, 8, 12, 24 and 48h after the end of irinotecan
infusion. For the other patients, a limited sampling strategy was
adopted and only four samples were obtained, namely at the end,
and 10min, 4 and 24h after the end of irinotecan infusion. For the
identification of gene polymorphisms, a blood sample was
obtained at patient’s inclusion, and leukocytes were prepared by
Ficoll gradient centrifugation. For the evaluation of the CYP3A4
status, patients received, at least 24h before chemotherapy, a dose
of 300mg of cortisol as an i.v. bolus. Urines were collected over
24h by fractions of 3, 3 and 18h, and blood samples were obtained
15 and 90min after cortisol administration.
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Figure 1 The metabolism of irinotecan in humans.
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HPLC technique with fluorometric detection, which derives from a
technique we developed earlier (Rivory and Robert, 1994). This
technique allowed the separation and quantification of irinotecan
and all its known metabolites, namely SN-38, SN-38G, APC and
NPC. Briefly, 500ml of methanol/1N hydrochloric acid (98:2, v/v)
were added to 250ml of plasma. The tubes were vortex-mixed for
10s, centrifuged at 10000g for 5min at 41C and 5mlo f1 N
hydrochloric acid was added to 600ml of the supernatant. Later, after
centrifugation at 10000g for 5min at 41C, 80ml of the supernatant
was injected into the HPLC system. For SN-38G estimation, the
samples were incubated with 1000IU of b-glucuronidase for 2h at
371C prior to deproteinisation. The HPLC equipment consists of a
Perkin Elmer 200 model with a fluorescence detector (FP-1520,
JASCO, Bouguenais, France). Separation of compounds was
achieved using a Symmetry Shield RP8 (5mm, 150 4.6mm; Waters,
Saint-Quentin-en-Yvelines, France) analytical column protected by a
Symmetry Shield RP8 precolumn (5mm, 3.9 20mm; Waters). The
mobile phase A was performed with a mixture of 75mM ammonium
acetate buffer (adjusted to pH 6 with acetic acid)/acetonitrile (85:15,
v/v). The mobile phase B was acetonitrile. A linear gradient from 0
to 25% phase B in 30min was used at a rate of 1mlmin
 1.T h e
fluorescence detector excitation and emission wavelengths were set
at 355 and 515nm, respectively. The limit of quantification was
1mgl
 1 for all products.
A limited sampling strategy was adopted for the 20 last patients
included in the study, based on the study of Canal et al (1996).
Individual pharmacokinetic parameters were calculated according
to a nonlinear mixed effects approach using NonMem program
(Version VI, level I). Irinotecan concentrations were adequately
fitted with a three-compartmental model. Posterior Bayesian
pharmacokinetic parameters were determined for each patient,
especially clearance, which allowed to calculate irinotecan AUC.
SN-38 plasma concentrations were analysed by considering
irinotecan data and using two additional compartments (i.e., central
and peripheral compartment for SN-38). SN-38G and APC
concentrations were analysed separately. For both SN-38G and
APC, a two-compartment model with first-order input was used. For
the validation of the limited sampling strategy, the AUC values of
irinotecan and its metabolites were calculated for the 28 data-rich
patients using the trapezoidal rule (non-compartmental approach)
and compared with those obtained using the population approach.
Metabolic and pharmacogenetic studies
Cortisol and 6b-hydroxycortisol were evaluated in urine using an
HPLC technique (Rouits et al, 2003). Extraction was performed
using an ethyl acetate/isopropanol mixture (85:15, v/v). HPLC was
performed, as described earlier, using UV absorbance at 244nm
for detection.
Genomic DNA was extracted from leukocytes using the QIAamp
s
DNA minikit from Qiagen or the DNA Isolation Kit from Roche
Molecular Diagnostics (Meylan, France). It was quantified by
spectrophotometry. Polymerase chain reactions (PCR) were per-
formed on genomic DNA using appropriate primers. Two poly-
morphisms were sought in genomic DNA: the TA repeat in the
UGT1A1 gene promoter (UGT1A1*28 genotype, rs8175347) and an
SNP in the promoter of the CES2 gene (830C4G; rs11075646).
UGT1A1*28 genotype was determined using the technique of
Pyrosequencing (Rouits et al, 2004). The CES2 genotype was
determined by sequencing of the amplified PCR products obtained
using the following primers: forward: 50-CTCCTGGGGTCTCCA
ATTCT-30; reverse: 50-GAAAGGTGGGTGTGGTAGGA-30.
Statistical studies
Statistics were performed using SPSS software (Chicago, IL, USA).
The a-error risk was classically chosen as 5%. All statistical tests
were bi-directional. Continuous variables were compared using the
Pearson coefficient of correlation. Fisher’s exact test was used to
study the relationships between drug response and toxicity and the
parameters studied. Owing to the high number of tests performed,
the Bonferroni correction was applied to decrease the probability
of detecting falsely positive relationships.
RESULTS
Clinical outcome
A total of 49 colorectal cancer patients entered the study; there
were 34 males and 15 females and their median age was 60 years,
similar for both genders (Table 1). All of them were treated
according to the protocol described above, with a total of 190
courses of treatment. Toxicity and overall survival were evaluable
for all patients, response for 47 patients and progression-free
survival for 35 patients (Table 1). Overall survival was 20% at 2
years. The median follow up of the patients was 540 days from the
onset of chemotherapy.
Pharmacokinetics of irinotecan
Pharmacokinetic studies were performed during the first course of
treatment in 28 patients with 10–13 blood samplings and in 20
additional patients with a limited sampling strategy. The UGT1A1
polymorphism was determined in 44 patients, the CES2 poly-
morphism in 48 patients and the 6b-hydroxycortisol/cortisol
urinary ratio (measured 3, 6 and 24h after the administration of
300mg cortisol) in 46 patients.
The mean pharmacokinetic parameters of irinotecan and its
metabolites as obtained using the Bayesian approach are presented
in Table 2. Comparison of AUC values obtained using the
trapezoidal rule and the population approach was done for the
28 patients with data-rich samplings and revealed coefficients of
correlation of 0.96, 0.95, 0.93 and 0.99 for irinotecan, SN-38,
Table 1 Clinical features of the patients entering the study
Patients included 49
Gender (M/F) 34/15
Median age (range) 60 (33–78)
Performance status (0/40) 27/20
Tumour site (colon/rectum/both) 29/16/4
Metastases (hepatic/extrahepatic) 35/14
Prior adjuvant therapy (yes/no) 19/30
Prior palliative therapy (yes/no) 9/40
Overall response (progression/stable disease/objective response) 10/25/11
Neutropoenia over 190 courses (grade 1/grade 2/gradeX3) 20/5/9
Diarrhoea over 190 courses (grade 1/grade 2/grade 3) 38/10/3
Median progression-free survival (days) 92
Median overall survival (months) 13
Table 2 Pharmacokinetic parameters of irinotecan and metabolites in 48
patients (Bayesian population approach)
Pharmacokinetic parameters of irinotecan
Total plasma clearance 31.5±6.8lh
 1
Volume of distribution at steady state (Vss) 328±253l
AUCs of irinotecan and metabolites (mghl
 1)
Irinotecan 10530±2713
SN-38 1133±337
SN-38G 4369±2165
APC 2205±1293
Results are given as mean±s.d.
Pharmacologic determinants of irinotecan activity
E Rouits et al
1241
British Journal of Cancer (2008) 99(8), 1239–1245 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sSN-38G and APC, respectively. Bayesian AUC values were used for
further correlation analyses.
There was a weakly significant correlation between the dose
administered and the AUC values of irinotecan and SN-38
(r¼0.311 and 0.265, respectively, P¼0.03 and 0.07). There were
also significant correlations between the AUC of irinotecan and
those of each of the metabolites (0.309oro0.522, 0.0002
oPo0.03). Only a slight, nonsignificant correlation was found
between the AUC values of SN-38 and SN-38G (r¼0.211, Po0.15).
A highly significant correlation existed between the AUC values of
APC and NPC (r¼0.857, Po10
 7). It is also remarkable that the
relative extent of glucuronidation of SN-38 (as defined by the ratio
of the AUC of SN-38G to that of SN-38, see Rivory et al, 1997) was
inversely correlated with the relative extent of the activation of
irinotecan (as defined by the ratio of the AUC of SN-38 to that of
irinotecan) (r¼ –0.426, P¼0.002).
Relationships between clinicobiological and
pharmacokinetic parameters
No relationship between treatment response, progression-free
survival or toxicity and any of the pharmacokinetic parameters
was evidenced. In contrast, several important biological constants
were significantly correlated to pharmacokinetic parameters.
Limited to the significant relationships after Bonferroni correction,
we observed that the pretreatment leukocyte and granulocyte
counts were significantly correlated with SN-38 AUC (or the
relative extent of activation) (r¼0.402, P¼0.004, Figure 2A), that
a series of hepatic parameters (alkaline phosphatase, transami-
nases and lactate dehydrogenase) were significantly corre-
lated with the AUC values of APC (or the relative extent of
metabolisation) (0.456oro0.576, 2 10
 5oPo0.0001, Figure 2B)
and that plasma creatinine was significantly correlated (or creati-
nine clearance inversely correlated) with the AUC value of SN-38G
(or the relative extent of glucuronidation) (0.318oro0.412,
0.004oPo0.03, Figure 2C).
Relationships between pharmacokinetic parameters and
metabolic predictors
The rare allele (seven TA repeats) frequency of UGT1A1 was 0.30
and the rare allele frequency (G) of CES2 was 0.14. Both genotype
distributions followed the Hardy–Weinberg equilibrium. There
was no relationship between the polymorphisms of UGT1A1 or
CES2 and any of the pharmacokinetic parameters obtained, the
mean values of each parameter being not significantly different in
wild-type or variant patients for either polymorphism. The
relationship between UGT1A1 polymorphism and SN-38G AUC
value especially failed to reach significance (P¼0.20). In contrast,
there was a consistent association between the 6b-hydroxycortisol/
cortisol ratio at 6h after cortisol injection and the AUC values of
APC (or the relative extent of metabolisation) (r¼0.437,
P¼0.002).
Relationships between clinicobiological parameters and
metabolic predictors
The relationships between the three metabolic predictors (UGT1A1
and CES2 polymorphisms and the 6b-hydroxycortisol/cortisol
ratio) and the clinical and biological parameters could be studied
in the whole set of patients, independent of the pharmacokinetic
data. The UGT1A1 polymorphism was significantly related to
the bilirubin plasma level: variant homozygous patients had a
mean bilirubin plasma level of 2.5 higher than heterozygous
(P¼3 10
 6) or common homozygous patients (P¼7 10
 7)
(Table 3). This was also the case for ALT transaminase when
comparing common and variant homozygous patients (P¼0.004).
Variant homozygous patients also had significantly lower plasma
sodium levels than heterozygous or common homozygous
patients, but the difference was only 3.6% (P¼0.001). This
polymorphism was a significant predictor of toxicity: 3 patients
out of 23 common homozygous underwent an episode of grade 41
neutropoenia during at least one of the four first courses of
treatment, whereas this was the case for 9 patients out of 21
heterozygous or variant homozygous (P¼0.042 with Fisher’s exact
test). No relationship could be evidenced between UGT1A1
polymorphism and treatment response- or progression-free
survival (Table 3).
The CES2 polymorphism was unrelated to any of the biological
parameters analysed, with the exception of plasma lactate
dehydrogenase, which was twice lower in common homozygous
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Figure 2 Charts representing the correlations between (A) SN-38 AUC
value (mgh
 1l
 1) and pretreatment granulocyte counts ( 10
9) r¼0.402,
P¼0.005; (B) APC AUC value (mgh
 1l
 1) and pretreatment plasma
alkaline phosphatase (IUl
 1) r¼0.576, P¼2 10
 5;( C) Relative extent
of glucuronidation (SN-38G/SN-38) and pretreatment creatinine clearance
(mlmin
 1) r¼0.412, P¼0.004.
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not significant after the Bonferroni correction). This polymor-
phism was unrelated to treatment response or progression-free
survival, but appeared as a modest predictor of diarrhoea: 8
patients out of 36 common homozygous underwent an episode of
grade 41 diarrhoea during at least one of the four first courses of
treatment, whereas this was the case for 1 patient out of 12 patients
having at least one variant allele (not significant) (Table 3).
The urinary 6b-hydroxycortisol/cortisol ratio was studied at
three different time intervals after the administration of 300mg
cortisol. There was a significant positive correlation between the
6-h ratio and the plasma transaminases level (r¼0.501,
P¼0.0003). There was a significant association between the 6-h
(and the 24-h) ratio and the risk of grade 41 toxicity: patients who
had encountered such an episode of neutropoenia or diarrhoea
during any of the four first courses of treatment had a 1.84-fold
higher 6-h ratio than patients who had not (P¼0.022). From these
data, it was possible to define a threshold above which the risk of
toxicity is maximal; using the method of Youden, it was possible to
optimise this threshold at 0.52, giving a sensitivity of 80% and a
specificity of 77%. The association between a high 6-h ratio and the
risk of toxicity is especially marked for diarrhoea: only 2 patients
out of 31 with a ratio o0.52 underwent grade 41 diarrhoea,
whereas this was the case for 8 patients out of 15 with a ratio
40.52 (P¼0.003, with the Fisher exact test) (Table 3).
DISCUSSION
The mean pharmacokinetic and metabolic parameters we obtained
for the 49 patients by Bayesian analysis were within the range of
the values usually obtained (Mathijssen et al, 2003) and the
dispersion of the values is also comparable. The correlation
between the dose of irinotecan administered and the AUCs of both
irinotecan and SN-38 has been observed in most pharmacokinetic
studies. The correlation between APC and NPC AUCs was expected
in view of the fact that these two metabolites are produced by the
same enzyme, CYP3A4, in two parallel pathways (Haaz et al,
1998a,b). However, the inverse correlation between the relative
extent of SN-38 glucuronidation and the relative extent of
irinotecan activation has never been mentioned in the published
pharmacokinetic studies. In other words, a high glucuronidation
rate is associated with a low rate of formation of SN-38. This would
tend to indicate that the formation of the glucuronide is inde-
pendent of the availability of SN-38 and that a fixed amount of
SN-38 is transformed into SN-38G, suggesting a saturation process.
There was no direct relationship between the pharmacokinetic
parameters and the clinical outcome, both for toxicity and efficacy.
Such pharmacokinetic–pharmacodynamic relationships have been
found in some studies (de Forni et al, 1994; Abigerges et al, 1995;
Sasaki et al, 1995; Canal et al, 1996) but not all (Catimel et al, 1995;
Rothenberg et al, 1996; Herben et al, 1999; Ma et al, 2000). For
instance, neutropoenia and diarrhoea could be predicted from
irinotecan and SN-38 AUCs in three original studies (Abigerges
et al, 1995; Sasaki et al, 1995; Canal et al, 1996). However, such
correlations were obtained in early dose-finding studies with a
large range of doses prescribed and, therefore, a large range of
AUC values. In phase III studies performed at a fixed dose, the
AUC range is usually too small to identify pharmacokinetic–
pharmacodynamic relationships.
A careful analysis of the relationships between the pharmaco-
kinetic parameters and the pretreatment biological constants has
revealed several important features. The leukocyte count was
associated with SN-38 AUC, which would suggest that a significant
part of the plasma SN-38 might originate from blood-nucleated
cells. The role of leukocytes in the activation of irinotecan has been
mentioned in a study of Cecchin et al (2005) who observed an
association between CES2 mRNA expression in peripheral blood
mononuclear cells and the level of irinotecan activation in patients’
plasma. The correlation between the level of conversion of
cortisol into 6b-hydroxycortisol, and the plasma levels of APC is
in agreement with the major role of CYP3A4 in this pathway of
transformation of irinotecan (Haaz et al, 1998b). The correlation
between plasma liver enzymes and the AUC of APC was
unexpected, as it has been shown that CYP3A activity was reduced
by 50% in patients with concurrent elevations in liver transami-
nases (Baker et al, 2004); however, it has also been shown that
CYP3A4 expression was associated with the occurrence of
metastases in osteosarcoma (Dhaini et al, 2003), which might
explain why patients with high cortisol conversion into
6b-hydroxycortisol had altered liver enzymes. Another interesting
observation is that creatinine clearance was inversely correlated
with SN-38G AUC. This would indicate that renal function plays a
major role in the disposition of SN-38G and that the elimination of
this metabolite is a determinant of its plasma concentration as
important as its formation from SN-38.
Table 3 Relationships between the metabolic predictors and efficacy and toxicity of the treatment
Predictor Genotype (patient nos.) Neutropoenia Diarrhoea Response Bilirubin ALT
UGT1A1 WT (23) 3 (13%) 4 (17%) 3/13/7 8.5±3.1 24.2
(0.04–0.23) (0.06–0.38)
HT (16) 9 (43%)* 4 (19%) 6/4/5 7.5±3.3 31.1
VAR (5) (0.24–0.63) (0.07–0.40) 0/4/1 18.6±3.5** 63.0***
CES2 WT (36) 8 (22%) 8 (22%) 7/15/12 9.6±4.6 33.7
(0.12–0.38) (0.12–0.38)
HT/VAR (11/1) 4 (33%) 1 (8%) 3/7/2 8.5±4.5 23.0
(0.14–0.61) (0–0.38)
Ratio 6b-hydroxycortisol/cortisol
o0.52 (31) 5 (23%) 2 (6%) 7/17/7 8.9±3.9 26.4
(0.07–0.33) (0–0.22)
40.52 (15) 7 (47%) 7 (47%)**** 3/6/7 10.0±5.6 40.2
(0.25–0.70) (0.25–0.70)
For UGT1A1 and CES2, the genotypes were homozygous wild type (WT), heterozygous (HT) or homozygous variant (VAR). For the CYP3A4 status, the ratio
6b-hydoxycortisol/cortisol was split at a threshold of 0.52, as described in the article. The number of patients in each group is indicated in text. For toxicity data, the number of
patients undergoing grade 42 toxicity (WHO grading) is indicated, with the corresponding percentage between parentheses and the 95% confidence intervals between
parentheses. For response, the number of patients with progression/stabilisation/objective response is indicated, using RECIST criteria. Mean bilirubin (mmoll
 ) and ALT values
(UIl
 1) for each group of patients are indicated. Asterisks indicate a significant difference between patients’ groups: *P¼0.042; **P¼3 10
 6; ***P¼0.004; and ****P¼0.03.
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cantly related to the SN38-G AUC value or to the extent of
glucuronidation as has been observed in other studies (Iyer et al,
2002; Rouits et al, 2004; Toffoli et al, 2006; Co ˆte ´ et al, 2007;
Ramchandani et al, 2007) whereas, as expected, the bilirubin
plasma levels were much higher in the variant homozygous
patients than in common homozygous and heterozygous patients.
Despite the absence of significant association with the glucur-
onidation rate of SN-38, the UGT1A1 polymorphism appeared to
be significantly associated with irinotecan toxicity, the patients
having at least one variant allele being at increased risk of
neutropoenia. This has been already shown to be in relation with
the decreased transcription rate of UGT1A1 when the promoter
harbours seven TA repeats, and to the subsequent decrease of
enzyme dosage for SN-38 detoxification. Our study thus confirms
the importance of the pre-therapeutic determination of the
UGT1A1 genotype for predicting irinotecan toxicity, and indicates
that heterozygous patients may be also at increased risk for
neutropoenia. Bilirubinemia by itself did not appear as a
predicting factor for irinotecan toxicity.
It is remarkable that the CYP3A4 status, defined by the
6b-hydoxycortisol/cortisol ratio, appears as a predictor of the
diarrhoea and, to a lesser extent, to the neutropoenia undergone by
the patients, which is an original and important observation. Few
studies, until recently, have evaluated the pharmacokinetics
of these metabolites, and no study establishing metabolic–
pharmacodynamic relationship is presently available. The mechan-
ism by which the CYP3A4 status influences the occurrence of
irinotecan-induced diarrhoea remains elusive, as the metabolites
of irinotecan produced in this pathway do not display cytotoxic
activity. It might be simply related to the hepatic dysfunction that
is associated with high cortisol biotransformation in this group of
patients. Nevertheless, it appears tempting to propose the use of a
pretreatment CY3A4 determination for predicting this major side
effect of irinotecan, using, for instance, the cortisol 6b-hydroxyla-
tion approach or another one, such as the determination of
midazolam clearance, which has been shown to be significantly
associated with irinotecan clearance (Mathijssen et al, 2004).
As a conclusion, our studies have revealed several interesting
tracks concerning the prediction of irinotecan toxicity and some
new insights on the metabolism–pharmacodynamic relationships
of this major drug. We confirm the use of UGT1A1 genotyping to
predict for haematological toxicity, both for homozygous and
heterozygous patients; we demonstrate also the potential impor-
tance of CYP3A4 status to predict for the occurrence of digestive
toxicity. We show in addition that SN-38G plasma levels are
associated with renal function, that the participation of blood cells
in irinotecan activation might be more important than previously
thought and that the extent of glucuronidation of SN-38 is
inversely related to the relative formation of SN-38 from
irinotecan. All these observations may improve the routine use
of irinotecan in colorectal cancer patients.
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